首页> 美国卫生研究院文献>Clinical Medicine. Cardiology >Transcatheter Aortic Valve Implantation (TAVI): Is it Time for This Intervention to be Applied in a Lower Risk Population?
【2h】

Transcatheter Aortic Valve Implantation (TAVI): Is it Time for This Intervention to be Applied in a Lower Risk Population?

机译:经导管主动脉瓣植入术(TAVI):是时候将该干预措施应用于低风险人群了吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients with severe aortic stenosis are sometimes not candidates for conventional open heart surgery because of severe deconditioning, excessive risk factors, and multiple comorbidities. Transcatheter aortic valve implantation (TAVI) is a relatively recent intervention, which was initially addressed to individuals with severe symptomatic aortic stenosis at substantial or prohibitive surgical risk. Despite the documented beneficial effects of this therapeutic intervention in certain carefully selected individuals, it has not yet been applied to lower risk patients. This is a review of the current literature and accumulated clinical data of this rapidly evolving invasive procedure in an attempt to resolve whether it can now be applied to a wider portion of patients with aortic stenosis.
机译:患有严重主动脉瓣狭窄的患者有时因严重的身体不适,过多的危险因素和多种合并症而不适合进行常规的心脏直视手术。经导管主动脉瓣植入术(TAVI)是一种相对较新的干预措施,最初针对具有严重或禁止手术风险的严重症状性主动脉瓣狭窄患者。尽管已记录了这种治疗干预措施对某些精心挑选的个体的有益作用,但尚未将其应用于低风险患者。本文是对这种迅速发展的侵入性治疗方法的最新文献和累积的临床数据的综述,以试图解决现在是否可以将其应用于更广泛的主动脉瓣狭窄患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号